Liquidia Corporation

We are deeply passionate and committed to the discovery, engineering, and development required to bring novel therapies to patients who need them most, and to the healthcare providers who care for them. Our current drive is toward improving the treatment of pulmonary arterial hypertension (PAH).

We will continue to combine our proprietary, innovative PRINT Technology with new and established medications, offering the potential for both better precision and improved clinical outcomes.

News Releases

SEP 10 2021

Liquidia to Participate at H.C. Wainwright 23rd Annual Global Investment Conference

MORRISVILLE, N.C. , Sept. 10, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Damian deGoa, Chief Executive Officer, will present at the H.C. Wainwright 23 rd Annual Global Investment Conference , which runs from September 13 – 15, 2021.
AUG 18 2021

FDA Completes On-site Pre-Approval Inspection of Liquidia’s Morrisville, North Carolina Facility

No Form 483 observations were issued during 5-day inspection MORRISVILLE, N.C. , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Food and Drug Administration (FDA) has completed an on-site Pre-Approval Inspection (PAI) of its Morrisville, North

btn News